Skip to content

Development and Clinical Evaluation of a System for Choosing Femoral Neck Fracture Internal Fixation Strategies Based on Deep Convolutional Neural Networks

Development and Clinical Evaluation of a System for Choosing Femoral Neck Fracture Internal Fixation Strategies Based on Deep Convolutional Neural Networks

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105735
Enrollment
Unknown
Registered
2025-07-09
Start date
2025-04-21
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture

Interventions

Experimental Group:When formulating the specific surgical plan, the DCNN-CDSS is first employed to evaluate the patients baseline information and CT cross-sectional images. The system outputs the post
Control group:All patients underwent conventional treatment with three parallel cannulated screws.

Sponsors

Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: (1) Patients hospitalized for femoral neck fracture; (2) Age >20 years and <60 years;

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Presence of pathological fractures or multiple fractures; (2) Open fractures or combined with severe soft tissue injuries; (3) Pre-existing severe comorbidities (e.g., kidney disease, neurological disorders, etc.) before the fracture;

Design outcomes

Primary

MeasureTime frame
Clinical failures include: nonunion, femoral head necrosis, a decrease of more than 18 points in the Harris Hip Score (HHS), and reoperation.;A reduction of >18 points in the Harris Hip Score (HHS);

Secondary

MeasureTime frame
Clinical failure was defined as: nonunion, femoral head necrosis, a reduction of >18 points in Harris Hip Score (HHS), or reoperation.;Occurrence of serious adverse events (SAEs) in clinical trials, including disability, life-threatening conditions, death, or malformation.;

Countries

China

Contacts

Public ContactWeitao Jia

Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University

2442608253@qq.com+86 186 5190 5573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026